R-CHOP is a combination of five drugs that work together to target and kill cancer cells. It’s a first-line treatment for aggressive non-Hodgkin’s lymphoma, a group of blood cancers. Most often, ...

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III ...

Chemotherapy drugs can shrink tumors or kill stray cancer cells left behind after surgery or radiation. It’s also a systemic treatment, meaning its purpose is to kill cancer cells throughout your body ...

Please provide your email address to receive an email when new articles are posted on . The regimen conferred a 71% complete response rate among older adults with newly diagnosed DLBCL. Median PFS and ...

Please provide your email address to receive an email when new articles are posted on . The addition of lenalidomide to R-CHOP chemotherapy improved survival outcomes among patients with newly ...

To participate in this study, patients were required to have a diagnosis of de novo DLBCL; be treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone (R-CHOP) with or without ...

The replacement of vincristine with Velcade (bortezomib) in the R-CHOP regimen for the treatment of transplantation-ineligible patients with newly diagnosed mantle cell lymphoma improved overall ...

This trial was looking at a short course of chemotherapy with a new drug called Zevalin for people over 60 years of age with diffuse large B cell non Hodgkin lymphoma. Zevalin is a radio labelled ...

Follicular lymphoma (FL) is the most frequent indolent lymphoma subtype, accounting for 10% to 20% of all non-Hodgkin lymphomas in Western countries. At time of diagnosis, most patients have advanced ...